Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/29211
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-10-26T07:40:42Z-
dc.date.available2022-10-26T07:40:42Z-
dc.date.issued2016-02-01-
dc.identifier.citationCeyhan, M. vd. (2016). "Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008-2014". Human Vaccines and Immunotherapeutics, 12(2), 308-313.en_US
dc.identifier.issn2164-5515-
dc.identifier.issn2164-554X-
dc.identifier.urihttps://doi.org/10.1080/21645515.2015.1078952-
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/21645515.2015.1078952-
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049732/-
dc.identifier.urihttp://hdl.handle.net/11452/29211-
dc.descriptionÇalışmada 30 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.tr_TR
dc.description.abstractSuccessful vaccination policies for protection from invasive pneumococcal diseases (IPD) dependent on determination of the exact serotype distribution in each country. We aimed to identify serotypes of pneumococcal strains causing IPD in children in Turkey and emphasize the change in the serotypes before and after vaccination with 7-valent pneumococcal conjugate vaccine (PCV-7) was included and PCV-13 was newly changed in Turkish National Immunization Program. Streptococcus pneumoniae strains were isolated at 22 different hospitals of Turkey, which provide healthcare services to approximately 65% of the Turkish population. Of the 335 diagnosed cases with S. pneumoniae over the whole period of 2008-2014, the most common vaccine serotypes were 19F (15.8%), 6B (5.9%), 14 (5.9%), and 3 (5.9%). During the first 5y of age, which is the target population for vaccination, the potential serotype coverage ranged from 57.5 % to 36.8%, from 65.0% to 44.7%, and from 77.4% to 60.5% for PCV-7, PCV-10, and PCV-13 in 2008-2014, respectively. The ratio of non-vaccine serotypes was 27.2% in 2008-2010 whereas was 37.6% in 2011-2014 (p=0.045). S. penumoniae serotypes was less non-susceptible to penicillin as compared to our previous results (33.7vs 16.5 %, p=0.001). The reduction of those serotype coverage in years may be attributed to increasing vaccinated children in Turkey and the increasing non-vaccine serotype may be explained by serotype replacement. Our ongoing IPD surveillance is a significant source of information for the decision-making processes on pneumococcal vaccination.en_US
dc.description.sponsorshipPfizeren_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBiotechnology & applied microbiologyen_US
dc.subjectImmunologyen_US
dc.subjectEpidemiologyen_US
dc.subjectSerotypesen_US
dc.subjectS. pneumoniaeen_US
dc.subjectSurveillanceen_US
dc.subjectTurkeyen_US
dc.subjectPneumococcal conjugate vaccineen_US
dc.subjectSequential introductionen_US
dc.subjectImmunization planen_US
dc.subjectEarly impacten_US
dc.subjectEpidemiologyen_US
dc.subjectEraen_US
dc.subject.meshAnti-bacterial agentsen_US
dc.subject.meshChild, preschoolen_US
dc.subject.meshFemaleen_US
dc.subject.meshHeptavalent pneumococcal conjugate vaccineen_US
dc.subject.meshHospitalsen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunization programsen_US
dc.subject.meshMaleen_US
dc.subject.meshMicrobial sensitivity testsen_US
dc.subject.meshPneumococcal infectionsen_US
dc.subject.meshPneumococcal vaccinesen_US
dc.subject.meshProspective studiesen_US
dc.subject.meshSerogroupen_US
dc.subject.meshStreptococcus pneumoniaeen_US
dc.subject.meshTurkeyen_US
dc.subject.meshVaccinationen_US
dc.subject.meshVaccines, conjugateen_US
dc.titleSerotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008-2014en_US
dc.typeArticleen_US
dc.identifier.wos000371745700019tr_TR
dc.identifier.scopus2-s2.0-84960948757tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Mikrobiyoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0001-5428-3630tr_TR
dc.identifier.startpage308tr_TR
dc.identifier.endpage313tr_TR
dc.identifier.volume12tr_TR
dc.identifier.issue2tr_TR
dc.relation.journalHuman Vaccines and Immunotherapeuticsen_US
dc.contributor.buuauthorÖzakın, Cüneyt-
dc.contributor.researcheridAAG-8392-2021tr_TR
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationSanayitr_TR
dc.identifier.pubmed26325175tr_TR
dc.subject.wosBiotechnology & applied microbiologyen_US
dc.subject.wosImmunologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ2 (Biotechnology & applied microbiology)en_US
dc.wos.quartileQ3 (Immunology)en_US
dc.contributor.scopusid57200678942en_US
dc.subject.scopusPneumococcal Vaccines; Streptococcus Pneumoniae; Haemophilus Influenzae GlpQ Proteinen_US
dc.subject.emtree10-valent pneumococcal conjugate vaccineen_US
dc.subject.emtree13-valent pneumococcal vaccineen_US
dc.subject.emtreeAntiinfective agenten_US
dc.subject.emtreePneumococcus vaccineen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBacteremiaen_US
dc.subject.emtreeBacterial meningitisen_US
dc.subject.emtreeBacterium isolationen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeClinical decision makingen_US
dc.subject.emtreeEmpyemaen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMinimum inhibitory concentrationen_US
dc.subject.emtreeNonhumanen_US
dc.subject.emtreePneumococcal infectionen_US
dc.subject.emtreePreschool childen_US
dc.subject.emtreePrevalenceen_US
dc.subject.emtreeProspective studyen_US
dc.subject.emtreeSepsisen_US
dc.subject.emtreeSerotypeen_US
dc.subject.emtreeStreptococcus pneumoniaeen_US
dc.subject.emtreeTurkey (republic)en_US
dc.subject.emtreeClassificationen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeDrug effectsen_US
dc.subject.emtreeHospitalen_US
dc.subject.emtreeImmunologyen_US
dc.subject.emtreeIsolation and purificationen_US
dc.subject.emtreeMicrobial sensitivity testen_US
dc.subject.emtreeMicrobiologyen_US
dc.subject.emtreeMulticenter studyen_US
dc.subject.emtreePneumococcal infectionsen_US
dc.subject.emtreePreventive health serviceen_US
dc.subject.emtreeSerotypeen_US
dc.subject.emtreeTurkeyen_US
dc.subject.emtreeVaccinationen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Ceyhan_vd_2016.pdf191.39 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons